<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112075</article-id><article-id pub-id-type="publisher-id">ACM-40450</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_18344310.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  原发脊柱肿瘤预后模型
  Prognostic Model of Primary Spinal Tumor
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>春兵</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潘</surname><given-names>俊朋</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>波</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>禇</surname><given-names>言琛</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>志杰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院脊柱外科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>524</fpage><lpage>532</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨原发性脊柱肿瘤患者的预后相关因素并建立预测模型。方法：检索SEER数据库 
   
  
    (https://seer.cancer.gov/) 2004~2015年诊断为原发性脊柱肿瘤的患者。利用单因素和Cox回归分析与原发性脊柱肿瘤患者预后相关的独立危险因素。利用R语言建立列线图并采用ROC曲线、校准曲线和DCA进行评价。利用风险评分的中位数将患者分为低风险组与高风险组并采用Kaplan-Meier (K-M)生存曲线比较高低风险患者的生存情况。结果：共135例患者被纳入本研究，其中男性75例。年龄、肿瘤病理分级和N分期是原发性脊柱肿瘤患者预后相关的独立危险因素。基于3个独立预后相关因素构建列线图，其C指数为0.769，其所对应的1、2和3年的ROC曲线下面积分别为0.885、0.843和0.786。列线图的校准曲线表明该列线图预测的1、2和3年总生存率与实际生存率之间具有良好的一致性。此外，DCA结果表明该列线图在预测原发性脊柱肿瘤患者1、2及3年总生存率中具有良好的临床效用。生存曲线结果也表明2组患者间预后具有显著差异(P &lt; 0.0001)。结论：基于年龄、肿瘤病理分级和N分期构建的列线图可以良好地预测原发性脊柱肿瘤患者的总生存率。
    Objective: To explore the prognostic factors of primary spinal tumor and establish a prognostic nomogram. Methods: The data of patients who diagnosed as primary spinal tumor between 2004~2015 were obtained from SEER database (https://seer.cancer.gov/). Univariate and multivariate Cox analyses were used to determined independent prognostic factors for primary spinal tumor patients. A nomogram was established with R and ROC curve, calibration curve, and DCA were selected to evaluate it. Patients were divided into low- and high-risk groups with the median risk score, and Kaplan-Meier survival curve was selected to show the prognosis of patients. Results: A total of 135 patients were included, including 75 male patients. Age, tumor grade and N stage were confirmed as independent prognostic factors. A nomogram was established based on three independent prognostic factors, with C-index was 0.769. The area under the ROC curve at 1-, 2-, and 3-year were 0.885, 0.843 and 0.786. The calibration curve showed favorable calibration of nomogram at 1-, 2-, and 3-year. Additionally, DCA indicated favorable clinical utilization of nomogram in predicting 1-, 2-, and 3-year overall survival for primary spinal tumor. Survival curve showed distinct prognosis between two groups (P &lt; 0.0001). Conclusion: A nomogram incorporated age, tumor grade and N stage can favorably predict the overall survival of patients with primary spinal tumor. 
   
   
  
 
</p></abstract><kwd-group><kwd>脊柱肿瘤，预测模型，预后，生存曲线, Spinal Tumor</kwd><kwd> Prediction Model</kwd><kwd> Prognostic</kwd><kwd> Survival Curve</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨原发性脊柱肿瘤患者的预后相关因素并建立预测模型。方法：检索SEER数据库 (https://seer.cancer.gov/) 2004~2015年诊断为原发性脊柱肿瘤的患者。利用单因素和Cox回归分析与原发性脊柱肿瘤患者预后相关的独立危险因素。利用R语言建立列线图并采用ROC曲线、校准曲线和DCA进行评价。利用风险评分的中位数将患者分为低风险组与高风险组并采用Kaplan-Meier (K-M)生存曲线比较高低风险患者的生存情况。结果：共135例患者被纳入本研究，其中男性75例。年龄、肿瘤病理分级和N分期是原发性脊柱肿瘤患者预后相关的独立危险因素。基于3个独立预后相关因素构建列线图，其C指数为0.769，其所对应的1、2和3年的ROC曲线下面积分别为0.885、0.843和0.786。列线图的校准曲线表明该列线图预测的1、2和3年总生存率与实际生存率之间具有良好的一致性。此外，DCA结果表明该列线图在预测原发性脊柱肿瘤患者1、2及3年总生存率中具有良好的临床效用。生存曲线结果也表明2组患者间预后具有显著差异(P &lt; 0.0001)。结论：基于年龄、肿瘤病理分级和N分期构建的列线图可以良好地预测原发性脊柱肿瘤患者的总生存率。</p></sec><sec id="s2"><title>关键词</title><p>脊柱肿瘤，预测模型，预后，生存曲线</p></sec><sec id="s3"><title>Prognostic Model of Primary Spinal Tumor</title><p>Chunbing Wu<sup>1</sup>, Junpeng Pan<sup>1</sup>, Bo Liu<sup>1</sup>, Yanchen Chu<sup>2</sup>, Zhijie Wang<sup>2</sup></p><p><sup>1</sup>Medical College of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Spine, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/14-1571913x4_hanspub.png" /></p><p>Received: Jan. 17<sup>th</sup>, 2021; accepted: Feb. 2<sup>nd</sup>, 2021; published: Feb. 20<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/14-1571913x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the prognostic factors of primary spinal tumor and establish a prognostic nomogram. Methods: The data of patients who diagnosed as primary spinal tumor between 2004~2015 were obtained from SEER database (https://seer.cancer.gov/). Univariate and multivariate Cox analyses were used to determined independent prognostic factors for primary spinal tumor patients. A nomogram was established with R and ROC curve, calibration curve, and DCA were selected to evaluate it. Patients were divided into low- and high-risk groups with the median risk score, and Kaplan-Meier survival curve was selected to show the prognosis of patients. Results: A total of 135 patients were included, including 75 male patients. Age, tumor grade and N stage were confirmed as independent prognostic factors. A nomogram was established based on three independent prognostic factors, with C-index was 0.769. The area under the ROC curve at 1-, 2-, and 3-year were 0.885, 0.843 and 0.786. The calibration curve showed favorable calibration of nomogram at 1-, 2-, and 3-year. Additionally, DCA indicated favorable clinical utilization of nomogram in predicting 1-, 2-, and 3-year overall survival for primary spinal tumor. Survival curve showed distinct prognosis between two groups (P &lt; 0.0001). Conclusion: A nomogram incorporated age, tumor grade and N stage can favorably predict the overall survival of patients with primary spinal tumor.</p><p>Keywords:Spinal Tumor, Prediction Model, Prognostic, Survival Curve</p><disp-formula id="hanspub.40450-formula14"><graphic xlink:href="//html.hanspub.org/file/14-1571913x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/14-1571913x7_hanspub.png" /> <img src="//html.hanspub.org/file/14-1571913x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>脊柱肿瘤发病率较低，约占全身骨肿瘤的6%~10% [<xref ref-type="bibr" rid="hanspub.40450-ref1">1</xref>]。其包括转移性脊柱肿瘤和原发性脊柱肿瘤，以前者较为多见。在原发性脊柱肿瘤中，常见组织学类型包括巨细胞瘤、脊索瘤、多发性骨髓瘤及其它肉瘤。手术、放疗和化疗是治疗脊柱肿瘤患者的主要手段，其中早期患者多采取手术治疗，而中晚期患者多采取放化疗手段。但是，由于肿瘤患者之间的异质性较大，当前治疗模式下脊柱肿瘤患者的预后尚不满意，多数患者对放化疗的效果不理想 [<xref ref-type="bibr" rid="hanspub.40450-ref2">2</xref>]。因此，建立预测原发性脊柱肿瘤患者总生存率的预测模型具有一定的临床意义，其可以评估患者预后并指导制定临床诊疗策略。由于原发性脊柱肿瘤整体发生率较低。因此为获取足够的样本量，本研究通过获取并分析美国国立癌症研究所监测、流行病学和结果(Surveillance Epidemiology and End Results, SEER)数据，以研究原发性脊柱肿瘤患者的生存相关因素并建立预测其1、2和3年总体生存率的列线图。</p></sec><sec id="s6"><title>2. 方法</title><sec id="s6_1"><title>2.1. 资料收集</title><p>本研究通过SEER数据库(SEER*Stat 8.3.6软件)回顾性收集2004年至2015年诊断为原发性脊柱肿瘤的患者。SEER数据库详细记录了1973年以来美国部分州县大量肿瘤患者的发病、病理、治疗及预后等信息，其具有数量大、临床资料相对全面的特点。</p></sec><sec id="s6_2"><title>2.2. 纳入和排除标准</title><p>纳入标准：① 2004年~2015年被诊断为脊柱肿瘤的患者；② 肿瘤原发部位为脊柱。</p><p>排除标准：① 存在既往肿瘤病史；② 重要临床信息未知，包括病理分期、AJCC分期、治疗信息、种族信息和肿瘤尺寸。</p></sec><sec id="s6_3"><title>2.3. 纳入指标及处理</title><p>本研究纳入研究的变量人口统计学信息、肿瘤特征信息和治疗信息。人口统计学信息包括年龄、性别和种族。肿瘤信息包括肿瘤病理分级、肿瘤T分期、肿瘤N分期、肿瘤M分期、肿瘤AJCC分期和肿瘤尺寸。治疗信息包括是否放疗、是否化疗和行手术治疗。</p></sec><sec id="s6_4"><title>2.4. 统计学分析</title><p>本研究采用R3.6.1和SPSS25.0软件进行数据分析。采用单因素Cox回归分析确定与原发性脊柱肿瘤患者生存相关的因素。将单因素Cox回归分析中有统计学意义(P &lt; 0.05)的变量纳入多因素Cox回归分析以确定独立危险因素。基于影响原发性脊柱肿瘤患者预后的独立危险因素，使用R软件中的“rms”和“regplot”程序包建立列线图。采用一致性指数(C-index)、受试者工作特征(Receiver operator characteristic, ROC)曲线、校正曲线和临床决策曲线(Decision curve analysis，DCA)验证模型的可靠性。最后，基于所建立的列线图将患者分为高风险和低风险三组，绘制生存曲线并利用Kaplan-Meier和Log-rank检验方法确定2组患者之间的预后差异。以P &lt; 0.05 (双侧)为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 基本信息</title><p>本研究共纳入135例患者。其中男性75例，女性60例；绝大多数患者为白人；所有患者基本特征见表1。所有患者随访时间为0~155个月，中位随访时间为36个月。57例患者在随访期间死亡，死亡率为42.2%。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic information of patients with primary spinal malignant tumo</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >结果</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >48.89 &#177; 21.47</td></tr><tr><td align="center" valign="middle" >种族</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >黑人</td><td align="center" valign="middle" >7 (5.2)</td></tr><tr><td align="center" valign="middle" >白人</td><td align="center" valign="middle" >118 (87.4)</td></tr><tr><td align="center" valign="middle" >其它</td><td align="center" valign="middle" >10 (7.4)</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女性</td><td align="center" valign="middle" >60 (44.4)</td></tr><tr><td align="center" valign="middle" >男性</td><td align="center" valign="middle" >75 (55.6)</td></tr><tr><td align="center" valign="middle" >病理分级</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1~2</td><td align="center" valign="middle" >75 (55.6)</td></tr><tr><td align="center" valign="middle" >3~4</td><td align="center" valign="middle" >60 (44.4)</td></tr><tr><td align="center" valign="middle" >手术</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >未进行</td><td align="center" valign="middle" >16 (11.9)</td></tr><tr><td align="center" valign="middle" >进行</td><td align="center" valign="middle" >119 (88.1)</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >放疗</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >未进行</td><td align="center" valign="middle" >70 (51.9)</td></tr><tr><td align="center" valign="middle" >进行</td><td align="center" valign="middle" >65 (48.1)</td></tr><tr><td align="center" valign="middle" >化疗</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >未进行</td><td align="center" valign="middle" >99 (73.3)</td></tr><tr><td align="center" valign="middle" >进行</td><td align="center" valign="middle" >36 (26.7)</td></tr><tr><td align="center" valign="middle" >肿瘤尺寸(cm)</td><td align="center" valign="middle" >59.26 &#177; 38.15</td></tr><tr><td align="center" valign="middle" >AJCC分期</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I~II</td><td align="center" valign="middle" >123 (91.1)</td></tr><tr><td align="center" valign="middle" >III~IV</td><td align="center" valign="middle" >12 (8.9)</td></tr><tr><td align="center" valign="middle" >T分期</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T1</td><td align="center" valign="middle" >108 (80.0)</td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >25 (18.5)</td></tr><tr><td align="center" valign="middle" >T3</td><td align="center" valign="middle" >2 (1.5)</td></tr><tr><td align="center" valign="middle" >N分期</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >N0</td><td align="center" valign="middle" >132 (97.8)</td></tr><tr><td align="center" valign="middle" >N1</td><td align="center" valign="middle" >3 (2.2)</td></tr><tr><td align="center" valign="middle" >M分期</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >M0</td><td align="center" valign="middle" >125 (92.6)</td></tr><tr><td align="center" valign="middle" >M1</td><td align="center" valign="middle" >10 (7.4)</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 原发性脊柱恶性肿瘤患者基本信息</p></sec><sec id="s7_2"><title>3.2. 原发性脊柱肿瘤患者预后相关因素</title><p>通过单因素Cox回归分析，患者年龄、肿瘤病理分级、AJCC分期、N分期、M分期、手术治疗情况和化疗情况被确定为与原发性脊柱肿瘤预后相关的因素(P &lt; 0.05) (表2)。将上述变量纳入多因素Cox回归分析，结果表明患者年龄、肿瘤病理分级和N分期是原发性脊柱肿瘤患者的独立预后相关因素(P &lt; 0.05) (表2)。随着年龄的增加、病理分级的增加和N分期的增加，患者的总生存率呈现降低的趋势。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Cox regression analysis of prognosis of patients with primary spinal malignant tumo</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="4"  >单因素Cox分析</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="4"  >多因素Cox分析</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >HR</td><td align="center" valign="middle"  colspan="2"  >95%置信区间</td><td align="center" valign="middle" >P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >HR</td><td align="center" valign="middle"  colspan="2"  >95%置信区间</td><td align="center" valign="middle" >P</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >1.023</td><td align="center" valign="middle"  colspan="2"  >1.009~1.037</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.031</td><td align="center" valign="middle"  colspan="2"  >1.015~1.046</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >种族</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >黑人</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.207</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >白人</td><td align="center" valign="middle" >0.433</td><td align="center" valign="middle"  colspan="2"  >0.172~1.093</td><td align="center" valign="middle" >0.076</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >其它</td><td align="center" valign="middle" >0.448</td><td align="center" valign="middle"  colspan="2"  >0.120~1.672</td><td align="center" valign="middle" >0.232</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女性</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男性</td><td align="center" valign="middle" >0.834</td><td align="center" valign="middle"  colspan="2"  >0.495~1.404</td><td align="center" valign="middle" >0.495</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >病理分级</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >1~2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >3~4</td><td align="center" valign="middle" >4.221</td><td align="center" valign="middle"  colspan="2"  >2.406~7.405</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.499</td><td align="center" valign="middle"  colspan="2"  >2.295~8.819</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >手术</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >未进行</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >进行</td><td align="center" valign="middle" >0.415</td><td align="center" valign="middle"  colspan="2"  >0.201~0.857</td><td align="center" valign="middle" >0.017</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.786</td><td align="center" valign="middle"  colspan="2"  >0.314~1.969</td><td align="center" valign="middle" >0.608</td></tr><tr><td align="center" valign="middle" >放疗</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >未进行</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >进行</td><td align="center" valign="middle" >0.857</td><td align="center" valign="middle"  colspan="2"  >0.508~1.447</td><td align="center" valign="middle" >0.564</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >化疗</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >未进行</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >进行</td><td align="center" valign="middle" >1.970</td><td align="center" valign="middle"  colspan="2"  >1.148~3.379</td><td align="center" valign="middle" >0.014</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.000</td><td align="center" valign="middle"  colspan="2"  >0.446~2.242</td><td align="center" valign="middle" >0.999</td></tr><tr><td align="center" valign="middle" >肿瘤尺寸</td><td align="center" valign="middle" >1.000</td><td align="center" valign="middle"  colspan="2"  >0.993~1.006</td><td align="center" valign="middle" >0.935</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >AJCC分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I~II</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >III~IV</td><td align="center" valign="middle" >5.543</td><td align="center" valign="middle"  colspan="2"  >2.733~11.244</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.021</td><td align="center" valign="middle"  colspan="2"  >0.249~16.401</td><td align="center" valign="middle" >0.510</td></tr><tr><td align="center" valign="middle" >T分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.575</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >1.026</td><td align="center" valign="middle"  colspan="2"  >0.530~1.985</td><td align="center" valign="middle" >0.940</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T3</td><td align="center" valign="middle" >2.914</td><td align="center" valign="middle"  colspan="2"  >0.397~21.396</td><td align="center" valign="middle" >0.293</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >N分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >N0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >N1</td><td align="center" valign="middle" >20.532</td><td align="center" valign="middle"  colspan="2"  >5.730~73.574</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >7.927</td><td align="center" valign="middle"  colspan="2"  >1.708~36.802</td><td align="center" valign="middle" >0.008</td></tr><tr><td align="center" valign="middle" >M分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >M0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >M1</td><td align="center" valign="middle" >5.754</td><td align="center" valign="middle"  colspan="2"  >2.758~12.004</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.214</td><td align="center" valign="middle"  colspan="2"  >0.137~10.743</td><td align="center" valign="middle" >0.862</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 原发性脊柱恶性肿瘤患者预后的Cox回归分析</p></sec><sec id="s7_3"><title>3.3. 预测原发性脊柱肿瘤患者预后的列线图的建立</title><p>基于多因素Cox回归结果，将3个独立预后相关因素纳入构建列线图，建立预测原发性脊柱肿瘤患者1、2和3年总生存率的列线图(图1)。根据每一变量的单独得分相加可得总分值，根据总分值垂直向下投射即可得到原发性脊柱肿瘤患者的1、2和3年总生存率的预测值(图1)。该列线图的C指数为0.769，其所对应的1、2和3年的ROC曲线下面积分别为0.885、0.843和0.786 (图2)。C指数和ROC曲线下面积均表明该列线图具有较高的区分度。列线图的校准曲线表明该列线图预测的1、2和3年总生存率与实际生存率之间具有良好的一致性(图3(A)~(C))。此外，DCA结果表明该列线图在预测原发性脊柱肿瘤患者1、2及3年总生存率中具有良好的临床效用(图4(A)~(C))。</p></sec><sec id="s7_4"><title>3.4. 基于列线图的危险分层系统</title><p>通过列线图预测个体患者危险评分，利用中位数将患者分为低风险组与高风险组。其中，68例患者纳入低风险组，67例患者纳入高风险组。低风险组和高风险组患者的死亡率分别为25.0%和59.7%。生存曲线结果也表明2组患者间预后具有显著差异(P &lt; 0.0001) (图5)。综上，基于列线图的危险分层系统可以将原发性脊柱肿瘤患者的生存进行显著区分。</p><p>图1. 预测原发性脊柱肿瘤患者总生存率的预后模型</p><p>图2. 预测原发性脊柱肿瘤患者总生存率的预后模型的ROC曲线</p><p>图3. 预测原发性脊柱肿瘤患者总生存率的预后模型的校准曲线</p><p>图4. 预测原发性脊柱肿瘤患者总生存率的预后模型的DCA曲线</p><p>图5. 基于列线图的高低风险患者的生存曲线</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>原发性脊柱肿瘤是一类罕见恶性肿瘤，发病率较低。本研究中，135例原发性脊柱肿瘤患者被纳入本研究，通过单因素及多因素Cox回归分析，确定了3项与原发性脊柱肿瘤患者预后相关的独立危险因素，包括年龄、病理分级和N分期。基于上述3项临床常见的指标所建立的列线图预后较高的区分度和临床应用价值，可以指导临床实践工作。</p><p>年龄是与恶性肿瘤较为相关的预后因素。随着年龄的增加，患者预后逐渐变差。Song等 [<xref ref-type="bibr" rid="hanspub.40450-ref3">3</xref>] 纳入536例脊柱软骨肉瘤患者，结果表明年龄 ≥ 60岁的患者总生存率显著低于年龄&lt;60岁的患者。在转移性脊柱肿瘤患者中，年龄似乎扮演着不一样的角色。Amelot等 [<xref ref-type="bibr" rid="hanspub.40450-ref4">4</xref>] 研究发现年轻的乳腺癌脊柱转移患者具有更差的预后，这可能与年轻患者诊断时多处于晚期肿瘤相关。但是，胡越皓等 [<xref ref-type="bibr" rid="hanspub.40450-ref5">5</xref>] 纳入45例脊柱转移癌患者进行回顾性分析。年龄在单因素分析中表现出与患者预后的相关性(P &lt; 0.05)，然而多因素结果却表明年龄不是患者预后的独立危险因素，这可能与纳入的样本量较小存在一定的关系。综上，年龄与原发或转移性脊柱肿瘤的预后可能存在一定的关系，但是还需将来进行前瞻性的深入研究，其中的作用机制也值得深入探讨，以指导临床实践工作。</p><p>病理分级是众多肿瘤的预后相关因素，病理分级越高，患者预后越差。Li等人 [<xref ref-type="bibr" rid="hanspub.40450-ref6">6</xref>] 纳入63,510例子宫内膜癌患者，生存分析结果表明肿瘤病理分级与患者总生存和肿瘤特异生存率均显著相关。Qi等人 [<xref ref-type="bibr" rid="hanspub.40450-ref7">7</xref>] 纳入6122例阴茎鳞状细胞癌患者，同样发现肿瘤病理分级与患者肿瘤特异生存率显著相关。在骨与软组织肿瘤领域，病理分级与患者预后的关系也得到了大量报道。Ye等 [<xref ref-type="bibr" rid="hanspub.40450-ref8">8</xref>] 纳入2170例四肢脂肪肉瘤患者，生存分析结果发现肿瘤病理分级与四肢脂肪肉瘤患者的总生存率和肿瘤特异生存率显著相关。此外，肿瘤病理分级与患者预后的相关性在成软骨型骨肉瘤 [<xref ref-type="bibr" rid="hanspub.40450-ref9">9</xref>]、滑膜肉瘤 [<xref ref-type="bibr" rid="hanspub.40450-ref10">10</xref>] 和软骨肉瘤 [<xref ref-type="bibr" rid="hanspub.40450-ref11">11</xref>] 中均得到了证实。</p><p>本研究还发现了N分期与原发性脊柱肿瘤患者预后显著相关。N分期是AJCC分期的重要组成部分，其代表淋巴结转移情况。N分期与多种骨肿瘤的预后存在相关性。Zhou等人 [<xref ref-type="bibr" rid="hanspub.40450-ref12">12</xref>] 研究发现AJCC N分期与尤文肉瘤患者总生存率显著相关。本研究首次证实了N分期与原发性脊柱肿瘤患者的预后相关性，并将其纳入列线图，以增加预测价值。</p><p>本研究也有一定的局限性。首先，本研究是一项回顾性研究，存在一定的偏移。其次，虽然是SEER大数据系统所提取的数据，但是由于原发性脊柱肿瘤发生率较低，本研究仅纳入135例患者。因此，样本量相对较少。最后，由于数据来源于公共数据库，部分与预后相关的指标未被记录，因此无法获取。</p><p>综上所述，年龄、病理分级和N分期是原发性脊柱肿瘤患者的独立预后因素。基于这3个因素建立的列线图可良好预测原发性脊柱肿瘤患者的总生存率。</p></sec><sec id="s9"><title>文章引用</title><p>吴春兵,潘俊朋,刘 波,禇言琛,王志杰. 原发脊柱肿瘤预后模型Prognostic Model of Primary Spinal Tumor[J]. 临床医学进展, 2021, 11(02): 524-532. https://doi.org/10.12677/ACM.2021.112075</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40450-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">李德亨, 陈鑫, 郝斌, 高阳, 曹依群. 脊柱原发性肿瘤的外科治疗进展[J]. 中华神经外科疾病研究杂志, 2018(17): 89-91.</mixed-citation></ref><ref id="hanspub.40450-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">张剑. 放射性粒子植入近距离照射治疗脊柱肿瘤的方法研究[J]. 系统医学, 2020(5): 114-116.</mixed-citation></ref><ref id="hanspub.40450-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Song, K., Lin, K., Guan, H. and Li, F. (2020) Conditional Survival Analysis for Spinal Chondrosarcoma Patients after Surgical Resection. Spine, 45, 1110-1117. https://doi.org/10.1097/BRS.0000000000003494</mixed-citation></ref><ref id="hanspub.40450-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Amelot, A., Terrier, L.-M., Cristini, J., Buffenoir, K., Pascal-Moussellard, H., Carpentier, A., Bonaccorsi, R., Le Nail, L.-R. and Mathon, B. (2020) Survival in Breast Cancer Patients with Spine Metastases: Prognostic Assessment Involving Molecular Markers. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 46, 1021-1027.  
https://doi.org/10.1097/BRS.0000000000003494</mixed-citation></ref><ref id="hanspub.40450-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">胡越皓, 沈宇辉, 张伟滨, 万荣. 脊柱转移性肿瘤的手术疗效及生存危险因素分析[J]. 骨科, 2019(10): 278-283.</mixed-citation></ref><ref id="hanspub.40450-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Fan, Y., Dong, Y., Cheng, Y., Zhou, J., Wang, Z., Li, X. and Wang, J. (2020) Development and Validation of Nomograms Predicting the Overall and the Cancer-Specific Survival in Endometrial Cancer Patients. Frontiers in Medicine, 7, Article ID: 614629. https://doi.org/10.21203/rs.3.rs-68463/v1</mixed-citation></ref><ref id="hanspub.40450-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Qi, F., Wei, X., Zheng, Y., Ren, X., Li, X. and Zhao, E. (2020) Incidence Trends and Survival Outcomes of Penile Squamous Cell Carcinoma: Evidence from the Surveillance, Epidemiology and End Results Population-Based Data. Annals of Translational Medicine, 8, 1428. https://doi.org/10.21037/atm-20-1802</mixed-citation></ref><ref id="hanspub.40450-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ye, L., Hu, C., Wang, C., Yu, W., Liu, F. and Chen, Z. (2020) Nomogram for Predicting the Overall Survival and Cancer-Specific Survival of Patients with Extremity Liposarcoma: A Population-Based Study. BMC Cancer, 20, 889-889. https://doi.org/10.1186/s12885-020-07396-x</mixed-citation></ref><ref id="hanspub.40450-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gao, Z., Zhou, S., Song, H., Wang, Y. and He, X. (2020) Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Chondroblastic Osteosarcoma Patients. Journal of Surgical Oncology, 122, 1676-1684.  
https://doi.org/10.1002/jso.26185</mixed-citation></ref><ref id="hanspub.40450-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Aytekin, M.N., Öztürk, R., Amer, K. and Yapar, A. (2020) Epidemiology, Incidence, and Survival of Synovial Sarcoma Subtypes: SEER Database Analysis. Journal of Orthopaedic Surgery (Hong Kong), 28, 1-12.  
https://doi.org/10.1177/2309499020936009</mixed-citation></ref><ref id="hanspub.40450-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Huang, R., Sun, Z., Zheng, H., Yan, P., Hu, P., Yin, H., Zhang, J., Meng, T. and Huang, Z. (2019) Identifying the Prognosis Factors and Predicting the Survival Probability in Patients with Non-Metastatic Chondrosarcoma from the SEER Database. Orthopaedic Surgery, 11, 801-810. https://doi.org/10.1111/os.12521</mixed-citation></ref><ref id="hanspub.40450-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Z., Wang, J., Fang, L., Ma, J. and Guo, M. (2020) A Nomogram for Predicting Overall Survival in Patients with Ewing Sarcoma: A SEER-Based Study. BMC Musculoskeletal Disorders, 21, Article No. 737.  
https://doi.org/10.1186/s12891-020-03706-3</mixed-citation></ref></ref-list></back></article>